Real-world outcomes of tafasitamab-lenalidomide in patients with transplant-ineligible R/R DLBCL from the PRO-MIND study

Blood Immunology & Cellular Therapy · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles